Cargando…

Design, synthesis, in vitro α-glucosidase inhibition, docking, and molecular dynamics of new phthalimide-benzenesulfonamide hybrids for targeting type 2 diabetes

In the present work, a new series of 14 novel phthalimide-benzenesulfonamide derivatives 4a–n were synthesized, and their inhibitory activity against yeast α-glucosidase was screened. The obtained results indicated that most of the newly synthesized compounds showed prominent inhibitory activity aga...

Descripción completa

Detalles Bibliográficos
Autores principales: Askarzadeh, Mohammad, Azizian, Homa, Adib, Mehdi, Mohammadi-Khanaposhtani, Maryam, Mojtabavi, Somayeh, Faramarzi, Mohammad Ali, Sajjadi-Jazi, Sayed Mahmoud, Larijani, Bagher, Hamedifar, Haleh, Mahdavi, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217978/
https://www.ncbi.nlm.nih.gov/pubmed/35732907
http://dx.doi.org/10.1038/s41598-022-14896-2
_version_ 1784731780455071744
author Askarzadeh, Mohammad
Azizian, Homa
Adib, Mehdi
Mohammadi-Khanaposhtani, Maryam
Mojtabavi, Somayeh
Faramarzi, Mohammad Ali
Sajjadi-Jazi, Sayed Mahmoud
Larijani, Bagher
Hamedifar, Haleh
Mahdavi, Mohammad
author_facet Askarzadeh, Mohammad
Azizian, Homa
Adib, Mehdi
Mohammadi-Khanaposhtani, Maryam
Mojtabavi, Somayeh
Faramarzi, Mohammad Ali
Sajjadi-Jazi, Sayed Mahmoud
Larijani, Bagher
Hamedifar, Haleh
Mahdavi, Mohammad
author_sort Askarzadeh, Mohammad
collection PubMed
description In the present work, a new series of 14 novel phthalimide-benzenesulfonamide derivatives 4a–n were synthesized, and their inhibitory activity against yeast α-glucosidase was screened. The obtained results indicated that most of the newly synthesized compounds showed prominent inhibitory activity against α-glucosidase. Among them, 4-phenylpiperazin derivative 4m exhibited the strongest inhibition with the IC(50) value of 52.2 ± 0.1 µM. Enzyme kinetic study of compound 4m proved that its inhibition mode was competitive and K(i) value of this compound was calculated to be 52.7 µM. In silico induced fit docking and molecular dynamics studies were performed to further investigate the interaction, orientation, and conformation of the target compounds over the active site of α-glucosidase. Obtained date of these studies demonstrated that our new compounds interacted as well with the α-glucosidase active site with the acceptable binding energies. Furthermore, in silico druglikeness/ADME/Toxicity studies of compound 4m were performed and predicted that this compound is druglikeness and has good ADME and toxicity profiles.
format Online
Article
Text
id pubmed-9217978
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-92179782022-06-24 Design, synthesis, in vitro α-glucosidase inhibition, docking, and molecular dynamics of new phthalimide-benzenesulfonamide hybrids for targeting type 2 diabetes Askarzadeh, Mohammad Azizian, Homa Adib, Mehdi Mohammadi-Khanaposhtani, Maryam Mojtabavi, Somayeh Faramarzi, Mohammad Ali Sajjadi-Jazi, Sayed Mahmoud Larijani, Bagher Hamedifar, Haleh Mahdavi, Mohammad Sci Rep Article In the present work, a new series of 14 novel phthalimide-benzenesulfonamide derivatives 4a–n were synthesized, and their inhibitory activity against yeast α-glucosidase was screened. The obtained results indicated that most of the newly synthesized compounds showed prominent inhibitory activity against α-glucosidase. Among them, 4-phenylpiperazin derivative 4m exhibited the strongest inhibition with the IC(50) value of 52.2 ± 0.1 µM. Enzyme kinetic study of compound 4m proved that its inhibition mode was competitive and K(i) value of this compound was calculated to be 52.7 µM. In silico induced fit docking and molecular dynamics studies were performed to further investigate the interaction, orientation, and conformation of the target compounds over the active site of α-glucosidase. Obtained date of these studies demonstrated that our new compounds interacted as well with the α-glucosidase active site with the acceptable binding energies. Furthermore, in silico druglikeness/ADME/Toxicity studies of compound 4m were performed and predicted that this compound is druglikeness and has good ADME and toxicity profiles. Nature Publishing Group UK 2022-06-22 /pmc/articles/PMC9217978/ /pubmed/35732907 http://dx.doi.org/10.1038/s41598-022-14896-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Askarzadeh, Mohammad
Azizian, Homa
Adib, Mehdi
Mohammadi-Khanaposhtani, Maryam
Mojtabavi, Somayeh
Faramarzi, Mohammad Ali
Sajjadi-Jazi, Sayed Mahmoud
Larijani, Bagher
Hamedifar, Haleh
Mahdavi, Mohammad
Design, synthesis, in vitro α-glucosidase inhibition, docking, and molecular dynamics of new phthalimide-benzenesulfonamide hybrids for targeting type 2 diabetes
title Design, synthesis, in vitro α-glucosidase inhibition, docking, and molecular dynamics of new phthalimide-benzenesulfonamide hybrids for targeting type 2 diabetes
title_full Design, synthesis, in vitro α-glucosidase inhibition, docking, and molecular dynamics of new phthalimide-benzenesulfonamide hybrids for targeting type 2 diabetes
title_fullStr Design, synthesis, in vitro α-glucosidase inhibition, docking, and molecular dynamics of new phthalimide-benzenesulfonamide hybrids for targeting type 2 diabetes
title_full_unstemmed Design, synthesis, in vitro α-glucosidase inhibition, docking, and molecular dynamics of new phthalimide-benzenesulfonamide hybrids for targeting type 2 diabetes
title_short Design, synthesis, in vitro α-glucosidase inhibition, docking, and molecular dynamics of new phthalimide-benzenesulfonamide hybrids for targeting type 2 diabetes
title_sort design, synthesis, in vitro α-glucosidase inhibition, docking, and molecular dynamics of new phthalimide-benzenesulfonamide hybrids for targeting type 2 diabetes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217978/
https://www.ncbi.nlm.nih.gov/pubmed/35732907
http://dx.doi.org/10.1038/s41598-022-14896-2
work_keys_str_mv AT askarzadehmohammad designsynthesisinvitroaglucosidaseinhibitiondockingandmoleculardynamicsofnewphthalimidebenzenesulfonamidehybridsfortargetingtype2diabetes
AT azizianhoma designsynthesisinvitroaglucosidaseinhibitiondockingandmoleculardynamicsofnewphthalimidebenzenesulfonamidehybridsfortargetingtype2diabetes
AT adibmehdi designsynthesisinvitroaglucosidaseinhibitiondockingandmoleculardynamicsofnewphthalimidebenzenesulfonamidehybridsfortargetingtype2diabetes
AT mohammadikhanaposhtanimaryam designsynthesisinvitroaglucosidaseinhibitiondockingandmoleculardynamicsofnewphthalimidebenzenesulfonamidehybridsfortargetingtype2diabetes
AT mojtabavisomayeh designsynthesisinvitroaglucosidaseinhibitiondockingandmoleculardynamicsofnewphthalimidebenzenesulfonamidehybridsfortargetingtype2diabetes
AT faramarzimohammadali designsynthesisinvitroaglucosidaseinhibitiondockingandmoleculardynamicsofnewphthalimidebenzenesulfonamidehybridsfortargetingtype2diabetes
AT sajjadijazisayedmahmoud designsynthesisinvitroaglucosidaseinhibitiondockingandmoleculardynamicsofnewphthalimidebenzenesulfonamidehybridsfortargetingtype2diabetes
AT larijanibagher designsynthesisinvitroaglucosidaseinhibitiondockingandmoleculardynamicsofnewphthalimidebenzenesulfonamidehybridsfortargetingtype2diabetes
AT hamedifarhaleh designsynthesisinvitroaglucosidaseinhibitiondockingandmoleculardynamicsofnewphthalimidebenzenesulfonamidehybridsfortargetingtype2diabetes
AT mahdavimohammad designsynthesisinvitroaglucosidaseinhibitiondockingandmoleculardynamicsofnewphthalimidebenzenesulfonamidehybridsfortargetingtype2diabetes